-
Stanford Spinout TwoStep Therapeutics Raises $62.5M as Lead Peptide-Drug Conjugate Clears FDA IND
TwoStep Therapeutics, a Stanford-born biotech, has secured $62.5 million in funding and received FDA clearance to begin human trials of its lead peptide-drug conjugate, marking a major step forward for next-generation targeted therapies.
-
Teitur Trophics Reports Successful Phase I Results for Novel Parkinson’s Disease Peptide TT-P34
Teitur Trophics has announced positive Phase I clinical trial results for TT-P34, a first-in-class peptide therapy being developed for Parkinson’s disease, marking an encouraging early step for a new treatment approach.
-
New Clinical Trial Explores TAK-664 for Immunoglobulin-Naïve Patients with Primary Immunodeficiency
A new study is investigating whether TAK-664, an already-approved subcutaneous IgG replacement therapy, can help patients newly starting treatment for primary immunodeficiency diseases reach and maintain healthy antibody levels.
-
New Trial Explores Peptide-Based Combination to Reawaken Immunotherapy in Resistant Cancers
A new Phase I/II trial will test whether combining bexmarilimab with nivolumab can help restore immune system effectiveness in melanoma and non-small cell lung cancer patients whose disease has stopped responding to standard immunotherapy.
-
New Clinical Trial Launches to Study Efruxifermin for Advanced Liver Scarring from NASH/MASH
A new multi-center clinical trial is underway to evaluate efruxifermin, an investigational peptide-based therapy, in patients with compensated cirrhosis caused by NASH/MASH.
-
New Phase 2/3 Trial Launches to Explore BNT327 Combination Therapy for Lung Cancer
A newly registered Phase 2/3 study will investigate whether BNT327, combined with chemotherapy and other investigational agents, can improve outcomes for patients with first-line non-small cell lung cancer.
-
Rollover Trial Ensures Continued Access to Promising KRAS-Targeted Peptide Therapy Opnurasib
A new Novartis-sponsored rollover study will allow patients who are already benefiting from opnurasib (JDQ443) to continue their treatment while safety monitoring continues.
-
New Clinical Trial Explores Peptide-Targeted Radiotherapy for GRPR-Positive Tumors
A new Phase 1-1b study will investigate a peptide-receptor targeted radioligand approach for treating advanced solid tumors that express the GRPR receptor, combining precision imaging with targeted therapy.
-
New Clinical Trial Explores Long-Term Tirzepatide Treatment for Adolescents with Obesity
A new study, SURMOUNT-ADOLESCENTS-2, will examine how extended tirzepatide treatment combined with healthy lifestyle habits affects bodyweight and cardiovascular risk factors in teens with obesity.
-
New Clinical Trial Explores Combination Therapy for Metastatic Soft Tissue Sarcoma
A new clinical trial is investigating whether combining zanzalintinib with immunotherapies ipilimumab and nivolumab could offer a promising treatment strategy for patients with metastatic soft tissue sarcoma.